Anti-B7-H1 / PD-L1 / CD274 Reference Antibody is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab)is more than 100% ,determined by SEC-HPLC.
Immobilized human PD L1 His at 2 µg/mL can bind Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab),EC50=0.005894µg/mL.
Human PD-L1 CHO-K cells were stained with Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC263=1.533 nM.
The endocytosis ratio atezolizumab by HCC827 increased with the increase of antibody concentration, and the Internalization Rate (%) reached 60% at antibody concentration of 0.5 nM.
Atezolizumab inhibited the tumor growth of MC38 on C57BL/6N mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 85.2% at 2 mpk at D35.
* VAT and and shipping costs not included. Errors and price changes excepted
